OncoMatch/Clinical Trials/NCT05910177
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
Is NCT05910177 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Karelizumab combined with etoposide and cisplatin for carcinoma.
Treatment: Karelizumab combined with etoposide and cisplatin — This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage I, II
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Cannot have received: targeted drug therapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
HB ≥ 100g/L; WBC ≥ 3 × 10^9/L; ANC ≥ 1.5 × 10^9/L; PLT ≥ 100 × 10^9/L (no blood transfusion within 14 days)
Kidney function
Serum Cr ≤ 1x ULN; endogenous creatinine clearance rate >60 ml/min (Cockcroft Goult formula)
Liver function
BIL <1.5x ULN; ALT and AST <2.5x ULN; GPT ≤ 1.5x ULN
Cardiac function
No severe heart disease; no coronary heart disease of grade I or above; no arrhythmia (including prolonged QTc interval, female >470 ms); no cardiac dysfunction; no NYHA grade II or above heart failure; no unstable angina; no myocardial infarction within 1 year; no clinically significant supraventricular or ventricular arrhythmias that are still poorly controlled
The main organs function normally and meet the following standards: ... (see above for full details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify